stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Revenue growth
Grifols, S.A.'s revenue growth over the twelve months to 30 September 2026 was 10.9%, up 1.8 percentage points from fiscal 2025 (9.07%). Over the past ten years it has ranged from −4.32% (fiscal 2021) to 18.1% (fiscal 2022); the current reading is higher than 67% of that period. That is above the Drug Manufacturers General industry median of 6.72% and above the Healthcare sector median of 7.98%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 9.07% | (0.32) |
| FY2024 | 9.39% | (2.28) |
| FY2023 | 11.7% | 2.20 |
| FY2022 | 9.47% | (8.60) |
| FY2022 | 18.1% | 22.39 |
| FY2021 | −4.32% | (4.16) |
| FY2021 | −0.16% | (6.98) |
| FY2020 | 6.82% | 1.75 |
| FY2020 | 5.07% | (2.70) |
| FY2019 | 7.77% | (2.84) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 9.37% | 3.61 |
| Mar 2026 | 5.76% | (11.10) |
| Dec 2025 | 16.9% | 5.48 |
| Sep 2025 | 11.4% | (21.18) |
| 29 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| SNY Sanofi compare | 26.3% |
| NVO Novo Nordisk A/S compare | 11.1% |
| GRFS Grifols, S.A. | 10.9% |
| GSK GSK PLC Sponsored ADR compare | 6.90% |
| BMY Bristol Myers Squibb Company compare | 4.16% |
| BIIB Biogen Inc. compare | 2.30% |
| OGN Organon & Co. compare | −3.21% |
| AMRN Amarin Corporation PLC compare | −22.3% |
| NSRX Nasus Pharma Ltd. compare | — |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.98% |
| Market median | 7.71% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement